CalciMedica is a pioneering brand that focuses on the development of CRAC channel inhibitors for acute and chronic inflammatory conditions. Comprised of a team of scientists, physicians, drug development experts, and entrepreneurs, CalciMedica is dedicated to pioneering therapies for life-threatening inflammatory diseases with high unmet need. Their team includes leading experts in the field of CRAC channels, such as Chief Scientific Officer Kenneth Stauderman, Ph.

D., who has over 30 years of experience in drug discovery and development. Under the leadership of Chief Executive Officer Rachel Leheny, Ph. D., who has more than 30 years of experience in the life sciences industry, CalciMedica is committed to pushing the boundaries of scientific innovation.

They offer a range of products and services, including clinical trials for conditions such as acute and chronic pancreatitis, kidney diseases, and lung ailments. With a focus on developing effective treatments for these conditions, CalciMedica is dedicated to improving the lives of patients worldwide. Through their cutting-edge technologies and robust pipeline, CalciMedica strives to provide breakthrough solutions that address the unmet medical needs of individuals suffering from inflammatory diseases.

With a strong emphasis on developing safe and effective treatments, CalciMedica is at the forefront of medical innovation, offering hope to patients and their families